Therapeutic requirements in active ulcerative proctitis: A single-centre study.

[1]  T. Yamamoto,et al.  Consecutive monitoring of faecal calprotectin during mesalazine suppository therapy for active rectal inflammation in ulcerative colitis , 2015, Alimentary pharmacology & therapeutics.

[2]  S. Dalal,et al.  Systematic Review: Rectal Therapies for the Treatment of Distal Forms of Ulcerative Colitis , 2015, Inflammatory bowel diseases.

[3]  E. Doménech,et al.  Enfermedad Inflamatoria Intestinal al Día REVISIÓN Recomendaciones sobre el uso e indicaciones del tratamiento tópico en pacientes con colitis ulcerosa , 2019 .

[4]  C. J. van der Woude,et al.  Drug Therapies for Ulcerative Proctitis: Systematic Review and Meta-analysis , 2014, Inflammatory bowel diseases.

[5]  S. Nikolaus,et al.  Parameters of a severe disease course in ulcerative colitis. , 2014, World journal of gastroenterology.

[6]  G. Rogler,et al.  Topical therapy is underused in patients with ulcerative colitis. , 2014, Journal of Crohn's & colitis.

[7]  T. Hibi,et al.  Randomised clinical trial: evaluation of the efficacy of mesalazine (mesalamine) suppositories in patients with ulcerative colitis and active rectal inflammation – a placebo‐controlled study , 2013, Alimentary pharmacology & therapeutics.

[8]  J. Gisbert,et al.  Therapeutic guidelines on ulcerative colitis: a GRADE methodology based effort of GETECCU. , 2013, Gastroenterologia y hepatologia.

[9]  S. Vermeire,et al.  Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosis. , 2012, Journal of Crohn's & colitis.

[10]  S. Vermeire,et al.  Second European evidence-based Consensus on the diagnosis and management of ulcerative colitis: Current management , 2012 .

[11]  J. Gisbert,et al.  Adherence of gastroenterologists to European Crohn's and Colitis Organisation consensus on ulcerative colitis: a real-life survey in Spain. , 2010, Journal of Crohn's & colitis.

[12]  B. Flourié,et al.  Infliximab for refractory ulcerative proctitis , 2010, Alimentary pharmacology & therapeutics.

[13]  M. Thabane,et al.  Rectal 5-aminosalicylic acid for induction of remission in ulcerative colitis. , 2010, The Cochrane database of systematic reviews.

[14]  P. Dagnelie,et al.  Influence of Phenotype at Diagnosis and of Other Potential Prognostic Factors on the Course of Inflammatory Bowel Disease , 2009, The American Journal of Gastroenterology.

[15]  P. Munkholm,et al.  Changes in Clinical Characteristics, Course, and Prognosis of Inflammatory Bowel Disease during the Last 5 Decades: A Population‐Based Study from Copenhagen, Denmark , 2007, Inflammatory bowel diseases.

[16]  H. Steinhart,et al.  Clinical guidelines for the medical management of left‐sided ulcerative colitis and ulcerative proctitis: Summary statement , 2006, Inflammatory bowel diseases.

[17]  R. Bergman,et al.  Systematic review: the use of mesalazine in inflammatory bowel disease , 2006, Alimentary pharmacology & therapeutics.

[18]  A. Lavy,et al.  Budesonide foam versus budesonide enema in active ulcerative proctitis and proctosigmoiditis , 2006, Alimentary pharmacology & therapeutics.

[19]  J. Satsangi,et al.  Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. , 2005, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

[20]  R. Farmer,et al.  Clinical patterns, natural history, and progression of ulcerative colitis , 1993, Digestive Diseases and Sciences.

[21]  G. Haber,et al.  Double-blind, placebo-controlled evaluation of 5-ASA suppositories in active distal proctitis and measurement of extent of spread using99mTc-labeled 5-ASA suppositories , 1987, Digestive Diseases and Sciences.

[22]  P. Gionchetti,et al.  Topical treatment with 5-aminosalicylic in distal ulcerative colitis by using a new suppository preparation , 1990, International Journal of Colorectal Disease.

[23]  J. Mate,et al.  Role of 5-aminosalicylic acid (5-ASA) in treatment of inflammatory bowel disease: a systematic review. , 2002, Digestive diseases and sciences.

[24]  Caprilli,et al.  Rectal and colonic mesalazine concentration in ulcerative colitis: oral vs. oral plus topical treatment , 1999, Alimentary pharmacology & therapeutics.

[25]  P. Gionchetti,et al.  Comparison of oral with rectal mesalazine in the treatment of ulcerative proctitis , 1998, Diseases of the colon and rectum.

[26]  J. Marshall,et al.  Rectal corticosteroids versus alternative treatments in ulcerative colitis: a meta-analysis. , 1997, Gut.

[27]  A. V. van Bodegraven,et al.  Distribution of mesalazine enemas in active and quiescent ulcerative colitis. , 1996, Alimentary pharmacology & therapeutics.

[28]  Å. Danielsson,et al.  Pharmacokinetics of budesonide enema in patients with distal ulcerative colitis or proctitis , 1993, Alimentary pharmacology & therapeutics.

[29]  H. Adami,et al.  Ulcerative colitis and colorectal cancer. A population-based study. , 1990, The New England journal of medicine.

[30]  G. Porro,et al.  Mesalazine (5-aminosalicylic acid) suppositories in the treatment of ulcerative proctitis or distal proctosigmoiditis. A randomized controlled trial. , 1990, Scandinavian journal of gastroenterology.

[31]  J. V. van Tongeren,et al.  Effect of sulphapyridine, 5-aminosalicylic acid, and placebo in patients with idiopathic proctitis: a study to determine the active therapeutic moiety of sulphasalazine. , 1980, Gut.